SCYNEXIS Gains FDA QIDP and Fast Track Designations for SCY-247: 10 Years of Exclusivity and Accelerated Path Forward
Market Chameleon (Wed, 21-Jan 11:08 AM)
SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK—Milestone Payments Could Reach $145.5 Million
Market Chameleon (Thu, 20-Nov 11:45 AM)
